| Outcome Measures: |
Primary: Systolic Blood Pressure, Change From Baseline to End of Treatment, Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period|Diastolic Blood Pressure, Change From Baseline to End of Treatment, Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period|Pulse, Change From Baseline to End of Treatment, Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period|Weight, Change From Baseline to End of Treatment, Baseline is the day before first dose, end of treatment is last day of treatment|Clinically Relevant Change of Laboratory Variables, Number of participants with clinically relevant change of laboratory variables (clinical chemistry, haematology and urinalysis parameters, Measured regularly from day before first dose to day after last dose | Secondary: Area Under the Plasma Concentration vs Time Curve (AUC0-24) of AZD1656, Dose-adjusted to a total daily dose of 100 mg due to titrated doses, Measured last day of treatment|Maximum Plasma Concentration of AZD1656, Dose-adjusted to a morning dose of 50 mg due to titrated doses, Measured last day of treatment|Time to Reach Maximum Plasma Concentration of AZD1656, Measured last day of treatment|Terminal Elimination Half-life of AZD1656, Measured following the afternoon dose last day of treatment|Apparent Oral Clearance of AZD1656, Measured last day of treatment|P-Glucose (AUC0-24)/24, Change From Baseline to End of Treatment, Log ratio (End of treatment/Baseline) has been analysed in a mixed-effect ANOVA model, using treatment as fixed effect and log(Baseline) as covariate. Resulting estimates have been back-transformed from the log-scale and then multiplied by 100 to obtain the relative ratio (end of treatment/placebo) in percent., Baseline is the day before first dose, end of treatment is last day of treatment|S-Insulin (AUC0-24)/24, Change From Baseline to End of Treatment, Log ratio (End of treatment/Baseline) has been analysed in a mixed-effect ANOVA model, using treatment as fixed effect and log(Baseline) as covariate. Resulting estimates have been back-transformed from the log-scale and then multiplied by 100 to obtain the relative ratio (end of treatment/placebo) in percent., Baseline is the day before first dose, end of treatment is last day of treatment|S-C-Peptide (AUC0-24)/24, Change From Baseline to End of Treatment, Log ratio (End of treatment/Baseline) has been analysed in a mixed-effect ANOVA model, using treatment as fixed effect and log(Baseline) as covariate. Resulting estimates have been back-transformed from the log-scale and then multiplied by 100 to obtain the relative ratio (end of treatment/placebo) in percent., Baseline is the day before first dose, end of treatment is last day of treatment
|
